Radiation Oncologist at Dana Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School. Focus on prostate cancer and MRI guided radiation.
A novel master clinical trial applied to stereotactic MRI guided adaptive radiotherapy (SMART) demonstrates low rates of toxicity and highlights the benefits of the master protocol approach: oxford.ly/3XuGEGr@jonathan_leeman
In a new @JAMANetworkOpen study, @BenjaminKannMD & @DanaFarber researchers developed an AI model to diagnose muscle wasting, known as sarcopenia, using CT scans in patients with head and neck cancer, aiding timely interventions.
Release here ➡️ ms.spr.ly/60149JXU8
Join us Sept. 22 for the X-Ray-Guided Online Adaptive Radiotherapy Symposium in Dallas! This symposium will provide a full day of presentations and interactive sessions with leading experts in adaptive radiotherapy.
For more info and registration: bit.ly/3OpfZHp
Happy to share our latest study. We validated our deep learning ENE algorithm in the context of the @eaonc E3311 HPV OPC de-escalation trial.
Congratulations and a huge thank you all the co-authors for their help on this large, multi-institutional effort.
1/x
📢 CALL FOR PAPERS - We are inviting submissions to a collection on #cancer therapy #toxicity, guest edited by Drs. Raymond Mak (@Dr_RayMak), Miranda Fidler-Benaoudia (@MirandaFidlerB) & Lova Sun. Find out more: ow.ly/GGAK50Ngy5p
📢Pleased to announce the recipients of the inaugural
☢️Radiation Oncology Accelerator Awards 🥇🥇
intended to foster collaborations between @DanaFarber/@BrighamWomens & @MGHCancerCenter #radonc
Incredibly deserving group of early-stage investigators 🔥👏
#teamscience
🆕Does PSA at time of salvage therapy after radical prostatectomy for prostate cancer matter? Tilki, D'Amico, and co-authors report multinational findings here: pubmed.ncbi.nlm.nih.gov/3685…
Abs#298 @ASCO#GU23 👉bit.ly/3E4TrX0: In pts with localized #prostatecancer (T1-T2; Gleason ≤ 3 4; PSA ≤ 20 ng/mL) ➡️ radiation (SBRT) associated with better urinary continence & sexual bother but more bowel bother after 2 yrs vs surgery @urotoday@PCFnews@Uromigos
Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology jamanetwork.com/journals/jam… (1/n)